HEMASURE FILING 510(K) BY YEAR-END FOR LEUKONET FILTER LEUKOCYTE REMOVAL SYSTEM; SEPRACOR SUBSIDIARY EXPECTS TO NET $15- $17 MIL. FROM INITIAL PUBLIC OFFERING
This article was originally published in The Gray Sheet
Executive Summary
HemaSure plans to file a 510(k) in the second half of 1994 for its lead product, the LeukoNet Filter for removing leukocytes from red blood cells and platelet concentrates, the Sepracor subsidiary notes in a March 10 registration statement with the Securities and Exchange Commission for an initial public offering.